Huvepharma Inc.January 17, 2025

FDA 483 - Huvepharma Inc. - January 17, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Huvepharma Inc.

Record Details

Huvepharma Inc., a drug manufacturer in Saint Louis, MO, was cited for three observations during an FDA inspection. The observations relate to inadequate master production records for lot and expiry codes, failure of the quality control unit to follow procedures during stability testing, and insufficient testing of components for harmful impurities. These issues indicate significant concerns regarding quality control and manufacturing process adherence.

Company: Huvepharma Inc.
Inspection Date: January 17, 2025
Product Type: Drugs
Office: Kansas City District Office
Person: Matthew M. Schuckmann

Open in Dashboard

ID · 875d9ca9-027b-4102-83fc-d5bac90bbbe1